Company intelligence / Profile preview

Diacures

Ownership: Private
Development stage: Preclinical

Overview

DiogenX is developing a first-in-class regenerative treatment for type 1 diabetes. Its lead program uses a recombinant protein to modulate the Wnt/β-catenin signaling pathway, aiming to regenerate pancreatic insulin-producing beta cells. The company has demonstrated efficacy in preventing and reversing diabetes in preclinical models, with significant increases in functional human beta cells and good tolerability observed in long-term animal studies[4].

Therapeutic areas: Endocrinology
Modalities: Recombinant proteinBiologic
Industry: Biotech

Partnerships

None publicly disclosed as of June 2025

Beyond the preview

Go deeper on Diacures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diacures.

Explore the full profile